{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:55:29Z","timestamp":1785383729551,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["309854"],"award-info":[{"award-number":["309854"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1245\/s10434-025-18343-0","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:22:42Z","timestamp":1758810162000},"page":"108-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Uptake of Risk Reducing Mastectomy in Older BRCA1\/2 and PALB2 Carriers Undergoing Genetic Testing after 60 Years of Age"],"prefix":"10.1245","volume":"33","author":[{"given":"Amel","family":"Melanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mashal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Ferroum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Basik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Francois","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyne","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarkis","family":"Meterissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipshita","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"18343_CR1","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.00531","volume":"39","author":"NJ Boddicker","year":"2021","unstructured":"Boddicker NJ, Hu C, Weitzel JN, et al. Risk of late-onset breast cancer in genetically predisposed women. J Clin Oncol. 2021;39:3430\u201340.","journal-title":"J Clin Oncol"},{"key":"18343_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10549-010-0805-3","volume":"124","author":"DM van der Kolk","year":"2010","unstructured":"van der Kolk DM, de Bock GH, Leegte BK, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 2010;124:643\u201351.","journal-title":"Breast Cancer Res Treat"},{"key":"18343_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10549-020-06072-9","volume":"187","author":"N Stjepanovic","year":"2021","unstructured":"Stjepanovic N, Lubinski J, Moller P, et al. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2021;187:515\u201323.","journal-title":"Breast Cancer Res Treat"},{"key":"18343_CR4","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1200\/JCO.22.01239","volume":"41","author":"S Yadav","year":"2023","unstructured":"Yadav S, Boddicker NJ, Na J, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023;41:1703\u201313.","journal-title":"J Clin Oncol"},{"key":"18343_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.breast.2011.01.006","volume":"20","author":"I Haroun","year":"2011","unstructured":"Haroun I, Graham T, Poll A, et al. Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer. Breast. 2011;20:254\u20138.","journal-title":"Breast"},{"key":"18343_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ygyno.2019.05.017","volume":"154","author":"C Salyer","year":"2019","unstructured":"Salyer C, Kobelka C, Barrie A, et al. Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2019;154:374\u20138.","journal-title":"Gynecol Oncol"},{"key":"18343_CR7","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1002\/ijc.28941","volume":"135","author":"S Saadatmand","year":"2014","unstructured":"Saadatmand S, Vos JR, Hooning MJ, et al. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study. Int J Cancer. 2014;135:2940\u20139.","journal-title":"Int J Cancer"},{"key":"18343_CR8","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1200\/JCO.2001.19.19.3938","volume":"19","author":"SK McDonnell","year":"2001","unstructured":"McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938\u201343.","journal-title":"J Clin Oncol"},{"key":"18343_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/cncr.34615","volume":"129","author":"KA Metcalfe","year":"2023","unstructured":"Metcalfe KA, Gronwald J, Tung NM, et al. The risks of cancer in older women with BRCA pathogenic variants: how far have we come? Cancer. 2023;129:901\u20137.","journal-title":"Cancer"},{"key":"18343_CR10","unstructured":"Daly MB, Pal T, Maxwell KN, et al: NCCN Guidelines(R) Insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024. J Natl Compr Canc Netw 21:1000-1010, 2023"},{"key":"18343_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"key":"18343_CR12","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/s41436-021-01151-8","volume":"23","author":"M Tischkowitz","year":"2021","unstructured":"Tischkowitz M, Balmana J, Foulkes WD, et al. Management of individuals with germline variants in PALB2: a clinical practice resource of the American college of medical genetics and genomics (ACMG). Genet Med. 2021;23:1416\u201323.","journal-title":"Genet Med"},{"key":"18343_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/jmedgenet-2020-107356","volume":"59","author":"R Marcinkute","year":"2022","unstructured":"Marcinkute R, Woodward ER, Gandhi A, et al. Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers. J Med Genet. 2022;59:133\u201340.","journal-title":"J Med Genet"},{"key":"18343_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-020-05699-y","volume":"182","author":"D Cragun","year":"2020","unstructured":"Cragun D, Weidner A, Tezak A, et al. Cancer risk management among female BRCA1\/2, PALB2, CHEK2, and ATM carriers. Breast Cancer Res Treat. 2020;182:421\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"18343_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3816\/CBC.2007.n.053","volume":"7","author":"TM Friebel","year":"2007","unstructured":"Friebel TM, Domchek SM, Neuhausen SL, et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer. 2007;7:875\u201382.","journal-title":"Clin Breast Cancer"},{"key":"18343_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ygyno.2013.12.014","volume":"132","author":"C Garcia","year":"2014","unstructured":"Garcia C, Wendt J, Lyon L, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol. 2014;132:428\u201333.","journal-title":"Gynecol Oncol"},{"key":"18343_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/cncr.26294","volume":"118","author":"MD Schwartz","year":"2012","unstructured":"Schwartz MD, Isaacs C, Graves KD, et al. Long-term outcomes of BRCA1\/BRCA2 testing: risk reduction and surveillance. Cancer. 2012;118:510\u20137.","journal-title":"Cancer"},{"key":"18343_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10549-024-07283-0","volume":"206","author":"H Assad","year":"2024","unstructured":"Assad H, Levitin M, Petrucelli N, et al. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1\/2 variants evaluated at a large urban comprehensive cancer center. Breast Cancer Res Treat. 2024;206:261\u201372.","journal-title":"Breast Cancer Res Treat"},{"key":"18343_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.breast.2021.08.015","volume":"60","author":"DG Evans","year":"2021","unstructured":"Evans DG, Gandhi A, Wisely J, et al. Uptake of bilateral-risk-reducing-mastectomy: prospective analysis of 7195 women at high-risk of breast cancer. Breast. 2021;60:45\u201352.","journal-title":"Breast"},{"key":"18343_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","volume":"148","author":"X Chai","year":"2014","unstructured":"Chai X, Friebel TM, Singer CF, et al. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014;148:397\u2013406.","journal-title":"Breast Cancer Res Treat"},{"key":"18343_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/gtmb.2008.0067","volume":"13","author":"MS Beattie","year":"2009","unstructured":"Beattie MS, Crawford B, Lin F, et al. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers. 2009;13:51\u20136.","journal-title":"Genet Test Mol Biomarkers"},{"key":"18343_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","volume":"121","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe K, Eisen A, Senter L, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;121:15\u201321.","journal-title":"Br J Cancer"},{"key":"18343_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.maturitas.2013.10.017","volume":"77","author":"CM van Driel","year":"2014","unstructured":"van Driel CM, Eltahir Y, de Vries J, et al. Risk-reducing mastectomy in BRCA1\/2 mutation carriers: factors influencing uptake and timing. Maturitas. 2014;77:180\u20134.","journal-title":"Maturitas"},{"key":"18343_CR24","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/pon.5166","volume":"28","author":"S Manoukian","year":"2019","unstructured":"Manoukian S, Alfieri S, Bianchi E, et al. Risk-reducing surgery in BRCA1\/BRCA2 mutation carriers: are there factors associated with the choice? Psychooncology. 2019;28:1871\u20138.","journal-title":"Psychooncology"},{"key":"18343_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108324","volume":"50","author":"C Apostolova","year":"2024","unstructured":"Apostolova C, Ferroum A, Alhassan B, et al. Timing of genetic testing in BRCA1\/2 and PALB2-associated breast cancer: preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy. Eur J Surg Oncol. 2024;50:108324.","journal-title":"Eur J Surg Oncol"},{"key":"18343_CR26","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1200\/OP.20.00571","volume":"17","author":"J Armstrong","year":"2021","unstructured":"Armstrong J, Lynch K, Virgo KS, et al. Utilization, timing, and outcomes of BRCA genetic testing among women with newly diagnosed breast cancer from a national commercially insured population: the ABOARD study. JCO Oncol Pract. 2021;17:e226\u201335.","journal-title":"JCO Oncol Pract"},{"key":"18343_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.breast.2022.12.001","volume":"67","author":"Q Ain","year":"2022","unstructured":"Ain Q, Richardson C, Mutebi M, et al. Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients? Breast. 2022;67:30\u20135.","journal-title":"Breast"},{"key":"18343_CR28","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1245\/s10434-016-5328-7","volume":"23","author":"A Chiba","year":"2016","unstructured":"Chiba A, Hoskin TL, Hallberg EJ, et al. Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1\/BRCA2 mutation carriers with breast cancer. Ann Surg Oncol. 2016;23:3232\u20138.","journal-title":"Ann Surg Oncol"},{"key":"18343_CR29","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1200\/JCO-24-01334","volume":"43","author":"M Lambertini","year":"2025","unstructured":"Lambertini M, Blondeaux E, Tomasello LM, et al. Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA status. J Clin Oncol. 2025;43:1706\u201319.","journal-title":"J Clin Oncol"},{"key":"18343_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13053-025-00314-x","volume":"23","author":"SM Wong","year":"2025","unstructured":"Wong SM, Apostolova C, Ferroum A, et al. Chemotherapy receipt in affected BRCA1\/2 and PALB2 carriers with operable breast cancer: the impact of early detection and pre-diagnostic awareness on clinical outcomes and treatment. Hered Cancer Clin Pract. 2025;23:14.","journal-title":"Hered Cancer Clin Pract"},{"key":"18343_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.18486","volume":"7","author":"KN Wanis","year":"2024","unstructured":"Wanis KN, Kuerer HM, Sun SX, et al. Clinical outcomes for BRCA pathogenic variant carriers with breast cancer undergoing breast conservation. JAMA Netw Open. 2024;7:e2418486.","journal-title":"JAMA Netw Open"},{"key":"18343_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ygyno.2017.02.032","volume":"145","author":"J McGee","year":"2017","unstructured":"McGee J, Giannakeas V, Karlan B, et al. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: is preventive mastectomy warranted? Gynecol Oncol. 2017;145:346\u201351.","journal-title":"Gynecol Oncol"},{"key":"18343_CR33","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/cncr.27839","volume":"119","author":"PM Vencken","year":"2013","unstructured":"Vencken PM, Kriege M, Hooning M, et al. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1\/BRCA2 mutation carriers: implications for counseling. Cancer. 2013;119:955\u201362.","journal-title":"Cancer"},{"key":"18343_CR34","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/cncr.27842","volume":"119","author":"SM Domchek","year":"2013","unstructured":"Domchek SM, Jhaveri K, Patil S, et al. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer. 2013;119:1344\u20138.","journal-title":"Cancer"},{"key":"18343_CR35","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/jamasurg.2014.1081","volume":"149","author":"A Gangi","year":"2014","unstructured":"Gangi A, Cass I, Paik D, et al. Breast cancer following ovarian cancer in BRCA mutation carriers. JAMA Surg. 2014;149:1306\u201313.","journal-title":"JAMA Surg"},{"key":"18343_CR36","unstructured":"Oncology NCPGi: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. 2026"},{"key":"18343_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/jmg-2022-108898","volume":"60","author":"H Hanson","year":"2023","unstructured":"Hanson H, Kulkarni A, Loong L, et al. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2. J Med Genet. 2023;60:417\u201329.","journal-title":"J Med Genet"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18343-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18343-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18343-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:09:15Z","timestamp":1765289355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18343-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["18343"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18343-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported by award 309854 from the Fonds de Recherche du Quebec Sant\u00e9 (SW). J.-F.B. reports honoraria from Roche, Novartis, Genomic Health, Pfizer, Allergan, and Merck; personal fees from Roche, Genomic Health, NanoString Technologies, Pfizer, Eli Lilly, Novartis, and Merck; and travel support from Roche, GlaxoSmithKline, Novartis, Pfizer, and Lifecell outside the submitted work. I.P. reports honoraria from Roche outside of the submitted work. S.W. reports honoraria from AstraZeneca, Novartis, and Merck outside of the submitted work. E.W. declares Honoraria from Astrazeneca and Merck. W.F. declares group received research funds from Astra Zeneca. The remaining authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}